Edgeworth Economics’ Pharmaceutical Economics Practice Launches The Antitrust Prescription Blog

WASHINGTON--(BUSINESS WIRE)--Edgeworth Economics today debuts The Antitrust Prescription, the firm’s new blog that covers antitrust and other economic issues affecting companies in the pharmaceutical industry. In the blog, Edgeworth’s experts provide legal practitioners and pharmaceutical company leaders with the latest economic insights and information impacting business in this constantly-evolving industry.

The blog is an industry resource provided by Edgeworth’s Pharmaceutical Economics practice, which is dedicated to assisting companies and legal counsel with the most pressing economic issues in the space. With deep expertise in the pharmaceutical, healthcare and broader life sciences industries, Edgeworth’s coast-to-coast team of expert economists provides thoughtful and accessible insights on a regular basis to companies interested in the economic dimensions of common legal questions in the areas of antitrust and competition, false claims, product misrepresentation, consumer protection, intellectual property, valuation, and contract disputes. The Antitrust Prescription will spotlight economic topics surrounding legal issues including class certification, liability, and damages, and will provide expert commentary on common claims such as pay for delay, product hopping, exclusive contracting, monopolization, bid rigging, price fixing, and foreclosure.

Visit The Antitrust Prescription here and follow us on social media using #EE_TheAntitrustPrescription.

Learn more about Edgeworth’s Pharmaceutical Economics practice here.

Edgeworth Economics has deep experience analyzing economic and econometric issues in the pharmaceutical industry in the areas of antitrust, intellectual property, commercial damages, and consumer protection. Since our founding in 2009, Edgeworth’s economists have served as both testifying and consulting economists on a wide array of industry-specific matters before courts and regulatory authorities. Our pharmaceutical economics experts have assisted clients across the industry, including brand and generic pharmaceutical companies, biotechnology companies, product manufacturers, healthcare providers, and insurers.